Plasminogen activator inhibitor -1 levels in patients with primary varicose vein

Basit Öğe Kaydı
dc.authorscopusid15070597700
dc.authorscopusid7004009443
dc.authorscopusid8405312500
dc.authorscopusid6701417742
dc.authorscopusid56067103500
dc.authorscopusid56565260900
dc.authorscopusid7006617047
dc.contributor.authorErguzel N.
dc.contributor.authorYetkin E.
dc.contributor.authorErdem G.
dc.contributor.authorErdil N.
dc.contributor.authorYetkin G.
dc.contributor.authorHeper G.
dc.contributor.authorCelik T.
dc.date.accessioned2024-08-04T19:59:29Z
dc.date.available2024-08-04T19:59:29Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim. Plasmin is involved in extracellular matrix remodeling by activating some matrix metallo-proteinases and degrading extracellular matrix; therefore component of fibrinolytic system such as tissue plasminogen activator and plasminogen activators inhibitors (PAI-1) might have a role in the pathogenesis of vascular remodeling. In our study we aimed to investigate the levels of PAI-1 levels in patients with primary varicose veins (VV) and in their age and gender matched control group. Methods. Forty-one consecutive patients with peripheral varicose veins and 37 healthy age and gender-matched control subjects were included in the study from the outpatient cardiology and cardiovascular surgery clinic. Study population consisted of 41 consecutive patients who met the inclusion criteria and diagnosed as having class II primary VV according to CEAP classification. Routine biochemical and hematological analysis were performed in all patients and control subjects. Results. Plasma levels of PAI-1 were found to be lower in patients than those in control subjects (5.19±2.2 ng/mL vs. 6.47±2.6 ng/mL, P=0.025). Logistic regression analysis revealed that only the plasma levels of PAI-1 were found to be independently but inversely associated with the presence of primary VVs (Odds ratio: 0.80 CI: 0.64-0.99, P=0.04). Conclusion. We have shown that PAI-1 levels are significantly decreased in patients with pVVs and it has an independent association with the presence of pWs. However, its exact relation and role via matrix metlalloproteinases on the pathogenesis of the disease remains to be elucidated in further studies.en_US
dc.identifier.endpage180en_US
dc.identifier.issn0392-9590
dc.identifier.issue2en_US
dc.identifier.pmid22466984en_US
dc.identifier.scopus2-s2.0-84862213606en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage176en_US
dc.identifier.urihttps://hdl.handle.net/11616/90647
dc.identifier.volume31en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofInternational Angiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectExtracellular matrixen_US
dc.subjectFibrinolysinen_US
dc.subjectPlasminogen activatorsen_US
dc.titlePlasminogen activator inhibitor -1 levels in patients with primary varicose veinen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu